Fundraising FoxRoche Venture Fund — 2017 Investments
2 investments dated 2017 · listed companies and verified rows first · show all
Portfolio company that completed a successful 2018 biotech IPO, resulting in a 9x return for RiverVest.
BiotechSan Carlos, US
Nenad Tomasevic(Executive Officer)Christopher Bebbington(Executive Officer, Director)Alejandro Dorenbaum(Executive Officer)
BoardFarah Champsi(Director)inJohn McKearn(Director)inPeter Moldt(Director)
Co-investorsAlta PartnersLifeSci Venture PartnersNew Enterprise Associates (NEA)RiverVest Venture PartnersSamsara BioCapital
Takeda is a global pharmaceutical company that develops medicines and treatments for patients, focused on advancing science, technology, and partnerships to create new standards of care.
BiotechHealthtechTokyo, JP
Claudia D'Augusta(Executive Officer)inEduardo Bravo Fernandez de Araoz(Executive Officer, Director)Marie Paule Richard(Executive Officer)inWilfried Dalemans(Executive Officer)
BoardJune Almenoff(Director)Russell Greig(Director)
Co-investorsKleiner PerkinsRho VenturesYsios CapitalBrightlands Venture PartnersKreos Capital
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.